Element Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Element Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,448	Closed	-$2.64M	–	139
2025 Q1	$2.64M	Buy	+5,448	New	+$2.54M	0.66%	113
2018 Q4	–	Sell	-1,674	Closed	-$323K	–	904
2018 Q3	$323K	Buy	+1,674	New	+$298K	0.01%	571

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Element Capital Management's VRTX Position: Q2 2025 in Review

Element Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 5,448 shares — an estimated $2.64M sold.

Element Capital Management first reported a position in VRTX in Q3 2018 and held it in 2 quarters. The position peaked at $2.64M in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Element Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Element Capital Management sold 5,448 Vertex Pharmaceuticals shares in Q2 2025, an estimated $2.64M.
Element Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2018 and held it in 2 quarters.
Element Capital Management's Vertex Pharmaceuticals position peaked at $2.64M in Q1 2025.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Element Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.